# Glenmark Pharmaceuticals Ltd (GLENMARK)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹2393
Day Change: +0.59%
52W High: ₹2474
52W Low: ₹1370
Market Cap: ₹65,059 Cr

## Valuation
P/E: 61.18
P/B: 6.79
EPS: ₹37.68
Book Value: ₹339.57
Dividend Yield: 0%

## Returns
1Y Return: 26.68%

## Profitability
ROE: 0%
ROCE: 19.42%
Debt/Equity: 0.13
Revenue Growth: 15.1%
Profit Growth: 15.8%
EBITDA Margin: 24.41%
Operating Margin: 18.34%

## About
Glenmark Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Glenmark Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
- Announcement: Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
- Business Wire: BlinkRx Announces Availability of RYALTRIS® for Convenient Home Delivery Following Glenmark’s Commercial Transition

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:01.518Z
Price History Updated: 2026-05-18T22:58:07.069Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:07.069Z
Quant Updated: 2026-05-18T22:58:07.069Z
Sentiment Updated: 2026-05-18T22:58:07.069Z
Financials Status: current
Financials Updated: 2026-05-18T04:30:25.666Z
Financials Last Attempt: 2026-05-18T04:30:25.666Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹6005 Cr
Operating Profit: ₹1091 Cr (OPM 18%)
Net Profit: ₹546 Cr
Tax: ₹697 Cr

## Annual P&L History
Mar 2015: Rev ₹6005Cr | PAT ₹546Cr | OPM 18%
Mar 2016: Rev ₹6563Cr | PAT ₹209Cr | OPM 18%
Mar 2017: Rev ₹7562Cr | PAT ₹743Cr | OPM 19%

## Balance Sheet (Mar 2015)
Total Assets: ₹8427 Cr
Total Liabilities: ₹8427 Cr
Borrowings: ₹3267 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Glenn Mario Saldanha, Chairman, MD & CEO
- Cherylann Maria Pinto B.Pharm, Executive Director of Corporate Services & Executive Director
- Harish Vinayak Kuber, Company Secretary & Compliance Officer
- Alind  Sharma, President and Chief Human Resources Officer
- Ulhas R. Dhuppad, President & Head of Global Pharmaceutical Development

---
Source: rupiya.io/stocks/glenmark
Disclaimer: For research and education only. Not investment advice.